Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

361 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial.
Pang PS, Teerlink JR, Boer-Martins L, Gimpelewicz C, Davison BA, Wang Y, Voors AA, Severin T, Ponikowski P, Hua TA, Greenberg BH, Filippatos G, Felker GM, Cotter G, Metra M. Pang PS, et al. Among authors: teerlink jr. Am Heart J. 2017 May;187:62-69. doi: 10.1016/j.ahj.2017.02.024. Epub 2017 Feb 22. Am Heart J. 2017. PMID: 28454809 Free article. Clinical Trial.
Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4).
O'Connor CM, Gattis WA, Adams KF Jr, Hasselblad V, Chandler B, Frey A, Kobrin I, Rainisio M, Shah MR, Teerlink J, Gheorghiade M; Randomized Intravenous TeZosentan Study-4 Investigators. O'Connor CM, et al. Among authors: teerlink j. J Am Coll Cardiol. 2003 May 7;41(9):1452-7. doi: 10.1016/s0735-1097(03)00194-3. J Am Coll Cardiol. 2003. PMID: 12742280 Free article. Clinical Trial.
Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, Stangl K, Elkayam U, Teerlink JR, Frey A, Rainisio M, Kobrin I. Torre-Amione G, et al. Among authors: teerlink jr. J Am Coll Cardiol. 2003 Jul 2;42(1):140-7. doi: 10.1016/s0735-1097(03)00556-4. J Am Coll Cardiol. 2003. PMID: 12849674 Free article. Clinical Trial.
Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).
Teerlink JR, McMurray JJ, Bourge RC, Cleland JG, Cotter G, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, Van Veldhuisen DJ, Frey A, Rainisio M, Kobrin I; VERITAS Investigators. Teerlink JR, et al. Am Heart J. 2005 Jul;150(1):46-53. doi: 10.1016/j.ahj.2005.04.035. Am Heart J. 2005. PMID: 16084150
Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure.
Packer M, Abraham WT, Mehra MR, Yancy CW, Lawless CE, Mitchell JE, Smart FW, Bijou R, O'Connor CM, Massie BM, Pina IL, Greenberg BH, Young JB, Fishbein DP, Hauptman PJ, Bourge RC, Strobeck JE, Murali S, Schocken D, Teerlink JR, Levy WC, Trupp RJ, Silver MA; Prospective Evaluation and Identification of Cardiac Decompensation by ICG Test (PREDICT) Study Investigators and Coordinators. Packer M, et al. Among authors: teerlink jr. J Am Coll Cardiol. 2006 Jun 6;47(11):2245-52. doi: 10.1016/j.jacc.2005.12.071. Epub 2006 May 15. J Am Coll Cardiol. 2006. PMID: 16750691 Free article.
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I; VERITAS Investigators. McMurray JJ, et al. Among authors: teerlink jr. JAMA. 2007 Nov 7;298(17):2009-19. doi: 10.1001/jama.298.17.2009. JAMA. 2007. PMID: 17986694 Clinical Trial.
361 results